China is key market for Singaporean biotech start-up’s stomach cancer early diagnosis kit
The end of 2023 was “a very volatile period” because of factors such as the China property market crisis and the war in Gaza, and “we felt it wasn’t quite the right time” to move forward, Zhou said. According to the latest prospectus, the company’s revenue …